Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| granulocyte colony stimulating factor (G-CSF) type substances | 5678 | 1384099-30-2 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Eflapegrastim-xnst is a recombinant human granulocyte growth factor that binds to G-CSF receptors on myeloid progenitor cells and neutrophils, triggering signaling pathways that control cell differentiation, proliferation, migration and survival.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 9, 2022 | FDA | SPECTRUM PHARMS |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | L03AA19 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSTIMULANTS IMMUNOSTIMULANTS Colony stimulating factors |
| FDA CS | M0024696 | Granulocyte Colony-Stimulating Factor |
| FDA PE | N0000009451 | Increased Myeloid Cell Production |
| FDA EPC | N0000175666 | Leukocyte Growth Factor |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Febrile neutropenia caused by myelosuppressive anti-cancer drugs | indication | 409089005 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Granulocyte colony-stimulating factor receptor | Membrane receptor | AGONIST | Kd | 8.44 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| CHEBI:755956 | CHEBI |
| CHEMBL3833384 | ChEMBL_ID |
| C583329 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12180 | IUPHAR_LIGAND_ID |
| DB15001 | DRUGBANK_ID |
| 4041747 | VANDF |
| 4041748 | VANDF |
| C3641654 | UMLSCUI |
| 9918 | INN_ID |
| D11188 | KEGG_DRUG |
| 40936 | MMSL |
| d09923 | MMSL |
| 019179 | NDDF |
| UT99UG9QJX | UNII |
| 2612526 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Rolvedon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76961-101 | INJECTION, SOLUTION | 13.20 mg | SUBCUTANEOUS | BLA | 27 sections |
| Rolvedon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 82497-132 | INJECTION, SOLUTION | 13.20 mg | SUBCUTANEOUS | BLA | 27 sections |